– Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug –
– 70.6% of patients treated with STK-001. | December 3, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 10, 2021 GMT
BEDFORD, Mass. (BUSINESS WIRE) May 10, 2021
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2021 and provided business updates.
“The momentum we are seeing with STK-001 in the clinic is driven by high levels of interest from the Dravet community and our shared sense of urgency to advance a potential disease-modifying approach for the treatment of this devastating disease. The single dose portion of our Phase 1/2a MONARCH study in the U.S. is now fully enrolled up to the 30mg dose level and based on our progress, we now anticipate our first data readout from this single dose portion
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates
March 9, 2021 GMT
BEDFORD, Mass. (BUSINESS WIRE) Mar 9, 2021
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2020 and provided business updates.
“During the last year, the power and potential of RNA medicines became clear to the world. Simultaneously, the Stoke team advanced our efforts to discover and develop RNA-based medicines that aim to address the underlying cause of severe genetic diseases by selectively boosting protein production,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Our Phase 1/2a MONARCH study in children and adolescents with Dravet